Endocrine Gland Tumor clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Sorry, in progress, not accepting new patients
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
San Francisco 5391959, California 5332921 and other locations
Our lead scientists for Endocrine Gland Tumor research studies include Hyunseok Kang.
Last updated: